Tag: apixaban

1. The Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) cohort study evaluated the safety of standardized perioperative interruption of direct oral anticoagulants (DOACs) for patients with atrial fibrillation undergoing operative interventions. The rates of both major bleeding and arterial thrombosis were low during the study period. 2. Most patients had...
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer The risk of venous thromboembolism (VTE) is significantly increased in patients with active cancer. While parenteral prophylactic anticoagulation has been shown to reduce the risk of VTE in cancer patients, its use is associated with an increased risk of major bleeding...
Classics Series, Landmark Trials in Medicine
1. Apixaban was found to be non-inferior to conventional therapy (i.e., enoxaparin followed by warfarin) in the treatment of acute venous thromboembolism. 2. Major bleeding was found to be significantly less common in patients treated with apixaban as compared with conventional therapy. Original Date of Publication: August 2013 Study Rundown: New oral...
Classics Series, Landmark Trials in Medicine
Image: PD 1. Apixiban is superior to warfarin in preventing stroke in patients with atrial fibrillation 2. Apixaban has a decreased risk of intracranial hemorrhage compared to warfarin 3. There is no difference in GI bleeding risk between apixaban and warfarin. Original date of publication: September 15, 2011 Study Rundown: Warfarin is a vitamin...
Image: PD  1. Patients with venous thromboembolism (VTE) treated with the oral factor Xa inhibitor apixaban experienced similar outcomes to patients treated with enoxaparin and warfarin.  2. Patients treated with apixaban experienced significantly fewer adverse bleeding events.  Evidence Rating Level: 1 (Excellent)  Study Rundown: This safety and efficacy study showed that in uncomplicated patients...